- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07426757
En åpen studie for å evaluere PF-07994525 hos deltakere med avanserte kreftformer
En åpen merket fase 1-studie for å evaluere PF-07994525 hos deltakere med avanserte maligne sykdommer
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-post: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Rekruttering
- Arthur J.E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Har ikke rekruttert ennå
- Juravinski Cancer Centre
-
Toronto, Ontario, Canada, M5G2M9
- Rekruttering
- University Health Network- Princess Margaret Cancer Centre
-
-
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Presbyterian/St. Luke's Medical Center
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06511
- Rekruttering
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven, Connecticut, Forente stater, 06510
- Rekruttering
- Yale-New Haven Hospital-Yale Cancer Center
-
New Haven, Connecticut, Forente stater, 06510
- Rekruttering
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven, Connecticut, Forente stater, 06511
- Rekruttering
- Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
-
North Haven, Connecticut, Forente stater, 06473
- Rekruttering
- Smilow Cancer Hospital - North Haven
-
-
Florida
-
Coral Gables, Florida, Forente stater, 33146
- Rekruttering
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
-
Coral Springs, Florida, Forente stater, 33065
- Rekruttering
- Sylvester Comprehensive Cancer Center - Coral Springs
-
Deerfield Beach, Florida, Forente stater, 33442
- Rekruttering
- University of Miami Hospital and Clinics - Deerfield Beach
-
Doral, Florida, Forente stater, 33166
- Rekruttering
- Sylvester Comprehensive Cancer Center- Doral
-
Hollywood, Florida, Forente stater, 33021
- Rekruttering
- Sylvester Comprehensive Cancer Center - Hollywood
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- Sylvester Comprehensive Cancer Center
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami Hospital and Clinics
-
Miami, Florida, Forente stater, 33176
- Rekruttering
- Sylvester Comprehensive Cancer Center- Kendall
-
North Miami, Florida, Forente stater, 33181
- Rekruttering
- Sylvester Comprehensive Cancer Center - Sole Mia
-
Plantation, Florida, Forente stater, 33324
- Rekruttering
- Sylvester Comprehensive Cancer Center - Plantation
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Rekruttering
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Hospital
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Winship Cancer Institute, Emory University
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The James Cancer Hospital and Solove Research Institute
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- Ohio State University Hospitals
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The James Outpatient Care West Campus
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tristar BMT
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- TriStar Centennial Medical center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
-
Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
-
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
-
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1
Monotherapy Dose Expansion |
Oral administration Oral administration |
|
Eksperimentell: Part 2
Monotherapy Dose Escalation |
Oral administration |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Type, incidence and severity of participants with adverse events (AEs)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs) |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Type, incidence and severity of participants with laboratory abnormalities
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Number of participants with dose modifications
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Tidsramme: Baseline to end of DLT evaluation period
|
Occurrence of DLTs as defined by the protocol |
Baseline to end of DLT evaluation period
|
|
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 2: Recommended Dose for future development
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Safety, and preliminary anti-tumor activity |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objektiv responsrate (ORR) i henhold til International Myeloma Working Group (IMWG) responskriterier, fastsatt av undersøker.
Tidsramme: Fra basislinje til datoen for første dokumentasjon av sykdomsprogresjon, død eller start av ny antikreftbehandling (omtrent 2 år)
|
Fra basislinje til datoen for første dokumentasjon av sykdomsprogresjon, død eller start av ny antikreftbehandling (omtrent 2 år)
|
|
|
Fullstendig responsrate (CRR) i henhold til International Myeloma Working Group (IMWG) responskriterier, som fastsatt av undersøker.
Tidsramme: Baseline inntil datoen for første dokumentasjon av sykdomsprogresjon, død eller start av ny antikreftbehandling (omtrent 2 år)
|
Baseline inntil datoen for første dokumentasjon av sykdomsprogresjon, død eller start av ny antikreftbehandling (omtrent 2 år)
|
|
|
Tid til respons (TTR) per IMWG som bestemt av undersøker
Tidsramme: Utgangspunkt inntil datoen for første dokumentasjon av sykdomsprogresjon, død, eller start av ny antikreftbehandling (omtrent 2 år)
|
Utgangspunkt inntil datoen for første dokumentasjon av sykdomsprogresjon, død, eller start av ny antikreftbehandling (omtrent 2 år)
|
|
|
Varighet av respons (DOR) per IMWG som fastsatt av undersøkeren
Tidsramme: Baseline til datoen for første dokumentasjon av sykdomsprogresjon, død eller start på ny antikreftbehandling (omtrent 2 år)
|
Baseline til datoen for første dokumentasjon av sykdomsprogresjon, død eller start på ny antikreftbehandling (omtrent 2 år)
|
|
|
Varighet av fullstendig respons (DOCR) per IMWG som fastsatt av undersøker
Tidsramme: Fra baseline til datoen for første dokumentasjon av sykdomsprogresjon, død eller start på ny antikreftbehandling (omtrent 2 år)
|
Fra baseline til datoen for første dokumentasjon av sykdomsprogresjon, død eller start på ny antikreftbehandling (omtrent 2 år)
|
|
|
Progresjonsfri overlevelse (PFS) per IMWG som fastsatt av undersøker
Tidsramme: Baseline til datoen for den første dokumentasjonen av sykdomsprogresjon, død eller start av ny kreftbehandling (omtrent 2 år)
|
Baseline til datoen for den første dokumentasjonen av sykdomsprogresjon, død eller start av ny kreftbehandling (omtrent 2 år)
|
|
|
Total overlevelse (OS)
Tidsramme: Fra baseline til datoen for første dokumentasjon av sykdomsprogresjon, død eller start på ny antikreftbehandling (omtrent 2 år)
|
Fra baseline til datoen for første dokumentasjon av sykdomsprogresjon, død eller start på ny antikreftbehandling (omtrent 2 år)
|
|
|
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Cmin as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Accumulation ratio (Rac) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
AUC from time zero to time of last measurable concentration (AUClast)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Time to Maximum concentration (Tmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Maximum Observed Concentration (Cmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- C6331001
- KAT2i (Annen identifikator: Alias Study Number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .